{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T18:11:00Z","timestamp":1792001460001,"version":"4.4.0"},"reference-count":119,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>The \u03ba-opioid receptor (KOR) has recently emerged as an alternative therapeutic target for the development of pain medications, without deleterious side effects associated with the \u03bc-opioid receptor (MOR). However, modulation of KOR is currently under investigation for the treatment of depression, mood disorders, psychiatric comorbidity, and specific drug addictions. However, KOR agonists also trigger adverse effects including sedation, dysphoria, and hallucinations. In this respect, there is currently much debate on alternative paradigms. Recent effort has been devoted in search of biased ligands capable of selectively activating favorable signaling over signaling associated with unwanted side effects. On the other hand, the use of partial agonists is expected to allow the analgesia to be produced at dosages lower than those required to produce the adverse effects. More empirically, the unwanted central effects can be also avoided by using peripherally restricted agonists. In this review, we discuss the more recent trends in the design of KOR-selective, biased or partial, and finally, peripherally acting agonists. Special emphasis is given on the discussion of the most recent approaches for controlling functional selectivity of KOR-specific ligands.<\/jats:p>","DOI":"10.3390\/molecules28010346","type":"journal-article","created":{"date-parts":[[2023,1,2]],"date-time":"2023-01-02T03:08:59Z","timestamp":1672628939000},"page":"346","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["Design of \u03ba-Opioid Receptor Agonists for the Development of Potential Treatments of Pain with Reduced Side Effects"],"prefix":"10.3390","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4431-9094","authenticated-orcid":false,"given":"Federica","family":"Santino","sequence":"first","affiliation":[{"name":"Department of Chemistry \u201cG. Ciamician\u201d, University of Bologna, Via Selmi 2, 40126 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9134-3161","authenticated-orcid":false,"given":"Luca","family":"Gentilucci","sequence":"additional","affiliation":[{"name":"Department of Chemistry \u201cG. Ciamician\u201d, University of Bologna, Via Selmi 2, 40126 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,1,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Pasternak, C.W. (2011). Kappa opioid receptor function. The Opiate Receptors, Humana Press. [2nd ed.].","DOI":"10.1007\/978-1-60761-993-2"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Liu-Chen, L.-Y., and Inan, S. (2022). The Kappa Opioid Receptor, Handbook of Experimental Pharmacology, Springer. [1st ed.].","DOI":"10.1007\/978-3-030-89074-2"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2174\/1568026043451618","article-title":"Opioid receptors and their ligands","volume":"4","author":"Janecka","year":"2004","journal-title":"Curr. Top. Med. Chem."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.pharmthera.2009.05.008","article-title":"Kappa-opioid ligands in the study and treatment of mood disorders","volume":"123","author":"Carlezon","year":"2009","journal-title":"Pharm. Ther."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/164_2020_396","article-title":"The Role of Dynorphin and the Kappa Opioid Receptor in Schizophrenia and Major Depressive Disorder: A Translational Approach","volume":"Volume 271","author":"Inan","year":"2020","journal-title":"The Kappa Opioid Receptor. Handbook of Experimental Pharmacology"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1126\/science.6120570","article-title":"Dynorphin is a specific endogenous ligand of the kappa opioid receptor","volume":"215","author":"Chavkin","year":"1982","journal-title":"Science"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/164_2020_430","article-title":"Antinociceptive Effects of Kappa-Opioid Receptor Agonists","volume":"271","author":"Lazenka","year":"2022","journal-title":"Handb. Exp. Pharmacol."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Beck, T.C., Hapstack, M.A., Beck, K.R., and Dix, T.A. (2019). Therapeutic Potential of Kappa Opioid Agonists. Pharmaceuticals, 12.","DOI":"10.3390\/ph12020095"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"837671","DOI":"10.3389\/fphar.2022.837671","article-title":"The Kappa Opioid Receptor: A Promising Therapeutic Target for Multiple Pathologies","volume":"13","author":"Dalefield","year":"2022","journal-title":"Front. Pharmacol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/bs.irn.2017.08.001","article-title":"Dynorphin\/Kappa Opioid Receptor Signaling in Preclinical Models of Alcohol, Drug, and Food Addiction","volume":"136","author":"Karkhanis","year":"2017","journal-title":"Int. Rev. Neurobiol."},{"key":"ref_11","unstructured":"Liu-Chen, L.Y., and Inan, S. (2020). KOR Control over addiction processing: An exploration of the mesolimbic dopamine pathway. The Kappa Opioid Receptor. Handbook of Experimental Pharmacology, Springer."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3389\/fphar.2020.00057","article-title":"Crosstalk Between Kappa Opioid and Dopamine Systems in Compulsive Behaviors","volume":"11","author":"Casanova","year":"2020","journal-title":"Front. Pharmacol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"ra117","DOI":"10.1126\/scisignal.aai8441","article-title":"Biased Agonists of the Kappa Opioid Receptor Suppress Pain and Itch without Causing Sedation or Dysphoria","volume":"9","author":"Brust","year":"2016","journal-title":"Sci. Signal."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Faouzi, A., Varga, B.R., and Majumdar, S. (2020). Biased Opioid Ligands. Molecules, 25.","DOI":"10.3390\/molecules25184257"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Neto, J.A., Costanzini, A., De Giorgio, R., Lambert, D.G., Ruzza, C., and Cal\u00f2, G. (2020). Biased versus partial agonism in the search for safer opioid analgesics. Molecules, 25.","DOI":"10.3390\/molecules25173870"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/jcpt.12404","article-title":"Will peripherally restricted kappa-opioid receptor agonists (pKORAs) relieve pain with less opioid adverse effects and abuse potential?","volume":"41","author":"Boyd","year":"2016","journal-title":"J. Clin.Pharm. Ther."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"249","DOI":"10.2147\/CCID.S55942","article-title":"Nalfurafine hydrochloride to treat pruritus: A review","volume":"8","author":"Inui","year":"2015","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1007\/s40263-013-0101-y","article-title":"Nalmefene: A review of its use in the treatment of alcohol dependence","volume":"27","author":"Keating","year":"2013","journal-title":"CNS Drugs"},{"key":"ref_19","first-page":"517","article-title":"The effects of morphine- and nalorphine-like drugs in the nondependent and morphine-dependent chronic spinal dog","volume":"197","author":"Martin","year":"1976","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.cellsig.2017.01.016","article-title":"Nalfurafine is a G-protein biased agonist having significantly greater bias at the human than rodent form of the kappa opioid receptor","volume":"32","author":"Schattauer","year":"2017","journal-title":"Cell. Signal."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/j.1527-3458.2005.tb00270.x","article-title":"Bremazocine: A kappa-opioid agonist with potent analgesic and other pharmacologic properties","volume":"11","author":"Potter","year":"2005","journal-title":"CNS Drug Rev."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1021\/jm00352a005","article-title":"Benzeneacetamide amines: Structurally novel non-m.mu. opioids","volume":"25","author":"Szmuszkovicz","year":"1982","journal-title":"J. Med. Chem."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1517\/13543784.2010.515209","article-title":"Asimadoline in the treatment of irritable bowel syndrome","volume":"19","author":"Mangel","year":"2010","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/164_2020_431","article-title":"Kappa Opioid Receptor Ligands and Pharmacology: Diphenethylamines, a Class of Structurally Distinct, Selective Kappa Opioid Ligands","volume":"271","author":"Spetea","year":"2022","journal-title":"Handb. Exp. Pharmacol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"36703","DOI":"10.1074\/jbc.M113.504381","article-title":"Development of functionally selective, small molecule agonists at kappa opioid receptors","volume":"288","author":"Zhou","year":"2013","journal-title":"J. Biol. Chem."},{"key":"ref_26","first-page":"553","article-title":"Synth\u00e8se et \u00e9tude de l\u2019activit\u00e9 dopaminergique de d\u00e9riv\u00e9s de la di(ph\u00e9n\u00e9thyl)amine","volume":"13","author":"Nedelec","year":"1978","journal-title":"Eur. J. Med. Chem. Chim. Ther."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Schmidhammer, H., Erli, F., Guerrieri, E., and Spetea, M. (2020). Development of Diphenethylamines as Selective Kappa Opioid Receptor Ligands and Their Pharmacological Activities. Molecules, 25.","DOI":"10.3390\/molecules25215092"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"10302","DOI":"10.1021\/jm301258w","article-title":"Discovery and pharmacological evaluation of a diphenethylamine derivative (HS665), a highly potent and selective \u03ba opioid receptor agonist","volume":"55","author":"Spetea","year":"2012","journal-title":"J. Med. Chem."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1111\/bph.13854","article-title":"Selective k receptor partial agonist HS666 produces potent antinociception without inducing aversion after i.c.v. administration in mice","volume":"174","author":"Spetea","year":"2017","journal-title":"Br. J. Pharmacol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"7579","DOI":"10.1021\/acs.jmedchem.7b00981","article-title":"Highly Potent and Selective New Diphenethylamines Interacting with the \u03ba-Opioid Receptor: Synthesis, Pharmacology, and Structure-Activity Relationships","volume":"60","author":"Erli","year":"2017","journal-title":"J. Med. Chem."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Ortega, A., Blount, J.F., and Manchand, P.S. (1982). Salvinorin, a new trans-neoclerodane diterpene from Salvia divinorum (Labiatae). J. Chem. Soc. Perkin Trans. 1, 2505\u20132508.","DOI":"10.1039\/p19820002505"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"4716","DOI":"10.1021\/jo00198a026","article-title":"Divinorin A, a Psychotropic Terpenoid, and Divinorin B from the Hallucinogenic Mexican Mint Salvia divinorum","volume":"49","author":"Valdes","year":"1984","journal-title":"J. Org. Chem."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"3935","DOI":"10.1021\/ol016820d","article-title":"Salvinorin C, a New Neoclerodane Diterpene from a Bioactive Fraction of the Hallucinogenic Mexican Mint Salvia divinorum","volume":"3","author":"Valdes","year":"2001","journal-title":"Org. Lett."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1016\/j.bmcl.2018.03.029","article-title":"A Review of Salvinorin Analogs and their Kappa-Opioid Receptor Activity","volume":"28","author":"Roach","year":"2018","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ejphar.2013.10.050","article-title":"The 2-methoxy methyl analogue of salvinorin A attenuates cocaine-induced drug seeking and sucrose reinforcements in rats","volume":"720","author":"Morani","year":"2013","journal-title":"Eur. J. Pharmacol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/B978-0-12-420118-7.00012-3","article-title":"Salvinorin A Analogs and Other Kappa-Opioid Receptor Compounds as Treatments for Cocaine Abuse","volume":"69","author":"Kivell","year":"2014","journal-title":"Adv. Pharmacol."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Kivell, B.M., Paton, K.F., Kumar, N., Morani, A.S., Culverhouse, A., Shepherd, A., Welsh, S.A., Biggerstaff, A., Crowley, R.S., and Prisinzano, T.E. (2018). Kappa Opioid Receptor Agonist Mesyl Sal B Attenuates Behavioral Sensitization to Cocaine with Fewer Aversive Side-Effects than Salvinorin A in Rodents. Molecules, 23.","DOI":"10.3390\/molecules23102602"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1124\/jpet.114.216820","article-title":"The G protein-biased \u03ba-opioid receptor agonist RB-64 is analgesic with a unique spectrum of activities in vivo","volume":"352","author":"White","year":"2015","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/S0040-4020(01)97243-6","article-title":"Isolement et Analyse Structurale Du Collybolide, Nouveau Sesquiterpene Extrait de Collybia Maculata Alb. et Sch. Ex Fries (Basidiomycetes)","volume":"30","author":"Bui","year":"1974","journal-title":"Tetrahedron"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1021\/acscentsci.2c00442","article-title":"Asymmetric Syntheses of (+)- and (\u2212)-Collybolide Enable Reevaluation of kappa-Opioid Receptor Agonism","volume":"8","author":"Shevick","year":"2022","journal-title":"ACS Cent. Sci."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1208\/s12248-009-9105-4","article-title":"Peptide Kappa Opioid Receptor Ligands: Potential for Drug Development","volume":"11","author":"Aldrich","year":"2009","journal-title":"AAPS J."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2174\/1568026043451663","article-title":"New Trends in the Development of Opioid Peptide Analogues as Advanced Remedies for Pain Relief","volume":"4","author":"Gentilucci","year":"2004","journal-title":"Curr. Top. Med. Chem."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"3185","DOI":"10.2174\/138161210793292555","article-title":"Chemical Modifications Designed to Improve Peptide Stability: Incorporation of Non-Natural Amino Acids, Pseudo-Peptide Bonds, and Cyclization","volume":"16","author":"Gentilucci","year":"2010","journal-title":"Curr. Pharm. Des."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1124\/mol.112.083337","article-title":"Dynorphin\u2013Still an Extraordinarily Potent Opioid Peptide","volume":"83","author":"Chavkin","year":"2013","journal-title":"Mol. Pharmacol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1021\/jm020125+","article-title":"Structureactivity relationships of dynorphin A analogues modified in the address sequence","volume":"46","author":"Schlechtingen","year":"2003","journal-title":"J. Med. Chem."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1124\/jpet.104.065391","article-title":"FE200041 (D-Phe-D-Phe-D-Nle-D-Arg-NH2): A peripheral efficacious kappa opioid agonist with unprecedented selectivity","volume":"310","author":"Vanderah","year":"2004","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ejphar.2008.01.011","article-title":"Novel D-amino acid tetrapeptides produce potent antinociception by selectively acting at peripheral kappa-opioid receptors","volume":"583","author":"Vanderah","year":"2008","journal-title":"Eur. J. Pharmacol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"773204","DOI":"10.3389\/fphar.2021.773204","article-title":"Antinociceptive and Antipruritic Effects of HSK21542, a Peripherally-Restricted Kappa Opioid Receptor Agonist, in Animal Models of Pain and Itch","volume":"12","author":"Wang","year":"2021","journal-title":"Front. Pharmacol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"172396","DOI":"10.1016\/j.ejphar.2019.05.025","article-title":"Non-addictive orally-active kappa opioid agonists for the treatment of peripheral pain in rats","volume":"856","author":"Beck","year":"2019","journal-title":"Eur. J. Pharmacol."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Fugal, J., and Serpa, S.M. (Ann. Pharmacother., 2022). Difelikefalin: A New \u03ba-Opioid Receptor Agonist for the Treatment of Hemodialysis-Dependent Chronic Kidney Disease\u2013Associated Pruritus, Ann. Pharmacother., Online First.","DOI":"10.1177\/10600280221115889"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1080\/14728214.2021.2009799","article-title":"Emerging drugs for the treatment of postsurgical pain","volume":"26","author":"Turan","year":"2021","journal-title":"Expert Opin. Emerg. Drugs"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/S0140-6736(10)60354-6","article-title":"Ziconotide for treatment of severe chronic pain","volume":"375","author":"Schmidtko","year":"2010","journal-title":"Lancet"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1021\/acs.jmedchem.5b00911","article-title":"Conopeptide-derived \u03ba opioid agonists (Conorphins): Potent, selective, and metabolic stable dynorphin A mimetics with antinociceptive properties","volume":"59","author":"Brust","year":"2016","journal-title":"J. Med. Chem."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"9042","DOI":"10.1021\/acs.jmedchem.1c00158","article-title":"Design of a Stable Cyclic Peptide Analgesic Derived from Sunflower Seeds that Targets the \u03ba-Opioid Receptor for the Treatment of Chronic Abdominal Pain","volume":"64","author":"Koehbach","year":"2021","journal-title":"J. Med. Chem."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/386499a0","article-title":"A potent and selective endogenous agonist for the mu-opiate receptor","volume":"386","author":"Zadina","year":"1997","journal-title":"Nature"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1038\/sj.bjp.0702798","article-title":"The effects of endomorphin-1 and endomorphin-2 in CHO cells expressing recombinant mu-opioid receptors and SH-SY5Y cells","volume":"128","author":"Harrison","year":"1999","journal-title":"Br. J. Pharmacol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1124\/pr.59.1.3","article-title":"The endomorphin system and its evolving neurophysiological role","volume":"59","author":"Fichna","year":"2007","journal-title":"Pharmacol. Rev."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"5751","DOI":"10.1021\/acs.jmedchem.8b00296","article-title":"Constraining endomorphin-1 by beta,alpha-hybrid dipeptide\/heterocycle scaffolds: Identification of a novel kappa-opioid receptor selective partial agonist","volume":"61","author":"Bedini","year":"2018","journal-title":"J. Med. Chem."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"13390","DOI":"10.1002\/chem.201402519","article-title":"Synthesis and analysis of the conformational preferences of 5-aminomethyloxazolidine-2,4-dione scaffolds: First examples of \u03b22- and \u03b22,2-homo-Freidinger lactam analogues","volume":"20","author":"Greco","year":"2014","journal-title":"Chem. Eur. J."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"847","DOI":"10.7164\/antibiotics.55.847","article-title":"CJ-15,208, a novel kappa opioid receptor antagonist from a fungus, Ctenomyces serratus ATCC15502","volume":"55","author":"Saito","year":"2002","journal-title":"J. Antibiot."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"3647","DOI":"10.1016\/j.bmcl.2009.04.105","article-title":"Nascent structure-activity relationship study of a diastereomeric series of kappa opioid receptor antagonists derived from CJ-15,208","volume":"19","author":"Dolle","year":"2009","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1002\/cmdc.201100113","article-title":"Unexpected opioid activity profiles of analogues of the novel peptide kappa opioid receptor ligand CJ-15,208","volume":"6","author":"Aldrich","year":"2011","journal-title":"ChemMedChem"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1111\/j.1476-5381.2011.01544.x","article-title":"Novel opioid cyclic tetrapeptides: Trp isomers of CJ-15,208 exhibit distinct opioid receptor agonism and short-acting k opioid receptor antagonism","volume":"165","author":"Ross","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"3212","DOI":"10.1111\/bph.12664","article-title":"Alanine analogues of [D-Trp] CJ-15,208: Novel opioid activity profiles and prevention of drug- and stress-induced reinstatement of cocaine seeking behavior","volume":"171","author":"Aldrich","year":"2014","journal-title":"Br. J. Pharmacol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1021\/np300697k","article-title":"The macrocyclic peptide natural product CJ-15,208 is orally active and prevents reinstatement of extinguished cocaine-seeking behavior","volume":"76","author":"Aldrich","year":"2013","journal-title":"J. Nat. Prod."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1111\/bph.12132","article-title":"The macrocyclic tetrapeptide [D-Trp] CJ-15,208 produces short-acting k opioid receptor antagonism in the CNS after oral administration","volume":"169","author":"Eans","year":"2013","journal-title":"Br. J. Pharmacol."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Brice-Tutt, A.C., Senadheera, S.N., Ganno, M.L., Eans, S.O., Khaliq, T., Murray, T.F., McLaughlin, J.P., and Aldrich, J.V. (2020). Phenylalanine Stereoisomers of CJ-15,208 and [d-Trp] CJ-15,208 Exhibit Distinctly Different Opioid Activity Profiles. Molecules, 25.","DOI":"10.3390\/molecules25173999"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"5198","DOI":"10.1021\/jm0498811","article-title":"Synthesis and evaluation of the affinity toward \u03bc-opioid receptors of atypical, lipophilic ligands based on the sequence c[Tyr-Pro-Trp-Phe-Gly]","volume":"47","author":"Cardillo","year":"2004","journal-title":"J. Med. Chem."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1016\/j.peptides.2010.08.005","article-title":"Peripheral antinociceptive effects of the cyclic endomorphin-1 analog c[YpwFG] in a mouse visceral pain model","volume":"31","author":"Bedini","year":"2010","journal-title":"Peptides"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1002\/cmdc.201100169","article-title":"The inverse type II beta-turn on D-Trp-Phe, a pharmacophoric motif for MOR agonists","volume":"6","author":"Gentilucci","year":"2011","journal-title":"ChemMedChem"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"10292","DOI":"10.1021\/jm301213s","article-title":"Opioid activity profiles of oversimplified peptides lacking in the protonable N-terminus","volume":"55","author":"Tolomelli","year":"2012","journal-title":"J. Med. Chem."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"6861","DOI":"10.1021\/jm5002925","article-title":"Synthesis of tripeptides containing D-Trp substituted at the indole ring, assessment of opioid receptor binding and in vivo central antinociception","volume":"57","author":"Bedini","year":"2014","journal-title":"J. Med. Chem."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"185","DOI":"10.2174\/138945007779315704","article-title":"Re-discussion of the importance of ionic interactions in stabilizing ligand-opioid receptor complex and in activating signal transduction","volume":"8","author":"Gentilucci","year":"2007","journal-title":"Curr. Drug Targets"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.2174\/092986712799945030","article-title":"Molecular docking of opiates and opioid peptides, a tool for the design of selective agonists and antagonists, and for the investigation of atypical ligand-receptor interactions","volume":"19","author":"Gentilucci","year":"2012","journal-title":"Curr. Med. Chem."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"9255","DOI":"10.1021\/acs.jmedchem.6b00420","article-title":"Versatile Picklocks To Access All Opioid Receptors: Tuning the Selectivity and Functional Profile of the Cyclotetrapeptide c[Phe-D-Pro-Phe-Trp] (CJ-15,208)","volume":"59","author":"Bedini","year":"2016","journal-title":"J. Med. Chem."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"188","DOI":"10.3389\/fphar.2020.00188","article-title":"Functional selectivity and antinociceptive effects of a novel KOR agonist","volume":"11","author":"Bedini","year":"2020","journal-title":"Front. Pharmacol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.4155\/fmc-2017-0104","article-title":"Tryptophan-Containing Non-Cationizable Opioid Peptides\u2014A new chemotype with unusual structure and in vivo activity","volume":"9","author":"Gentilucci","year":"2017","journal-title":"Future Med. Chem."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/nrd3954","article-title":"Signalling bias in new drug discovery: Detection, quantification and therapeutic impact","volume":"12","author":"Kenakin","year":"2013","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"8019","DOI":"10.1021\/jm4010829","article-title":"Structure-activity relationships and discovery of a G protein biased _ opioid receptor ligand, [(3-methoxythiophen-2-yl) methyl] ({2-[(9R)-9-(pyridin-2-yl)-6-oxaspiro-[4.5] decan-9-yl]ethyl})amine (TRV130), for the treatment of acute severe pain","volume":"56","author":"Chen","year":"2013","journal-title":"J. Med. Chem."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1124\/jpet.112.201616","article-title":"A G protein-biased ligand at the \u03ba-opioid receptor is potently analgesic with reduced gastrointestinal and respiratory dysfunction compared with morphine","volume":"344","author":"DeWire","year":"2013","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/nature19112","article-title":"Structure-based discovery of opioid analgesics with reduced side effects","volume":"537","author":"Manglik","year":"2016","journal-title":"Nature"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1002\/jcph.207","article-title":"First clinical experience with TRV130: Pharmacokinetics and pharmacodynamics in healthy volunteers","volume":"54","author":"Soergel","year":"2014","journal-title":"J. Clin. Pharmacol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"e473","DOI":"10.1016\/j.bja.2020.09.021","article-title":"Approval of oliceridine (TRV130) for intravenous use in moderate to severe pain in adults","volume":"125","author":"Lambert","year":"2020","journal-title":"Br. J. Anaesth."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1111\/bph.14224","article-title":"The novel mu-opioid receptor agonist PZM21 depresses respiration and induces tolerance to antinociception","volume":"175","author":"Hill","year":"2018","journal-title":"Br. J. Pharmacol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/s41467-018-08162-1","article-title":"Phosphorylationdeficient G-protein-biased _-opioid receptors improve analgesia and diminish tolerance but worsen opioid side effects","volume":"21","author":"Kliewer","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1126\/science.286.5449.2495","article-title":"Enhanced morphine analgesia in mice lacking \u03b2-arrestin 2","volume":"286","author":"Bohn","year":"1999","journal-title":"Science"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1124\/mol.119.115956","article-title":"A biased view of \u03ba-opioid receptors?","volume":"96","author":"Conibear","year":"2019","journal-title":"Mol. Pharmacol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"e3140","DOI":"10.1126\/scisignal.aaz3140","article-title":"Low intrinsic efficacy for G protein activation can explain the improved side effect profiles of new opioid agonists","volume":"13","author":"Gillis","year":"2020","journal-title":"Sci. Signal."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"407","DOI":"10.3389\/fphar.2019.00407","article-title":"A Review of the Therapeutic Potential of Recently Developed G Protein-Biased Kappa Agonists","volume":"10","author":"Mores","year":"2019","journal-title":"Front. Pharmacol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.neuropharm.2013.06.011","article-title":"A novel, potent, oral active and safe antinociceptive pyrazole targeting kappa opioid receptors","volume":"73","author":"Trevisan","year":"2013","journal-title":"Neuropharmacology"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"3070","DOI":"10.1021\/acs.jmedchem.7b00109","article-title":"Structure-based discovery of new antagonist and biased agonist chemotypes for the kappa opioid receptor","volume":"60","author":"Zheng","year":"2017","journal-title":"J. Med. Chem."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"9b00195","DOI":"10.1021\/acschemneuro.9b00195","article-title":"Signaling properties of structurally diverse kappa opioid receptor ligands: Towards in vitro models of in vivo responses","volume":"10","author":"Dunn","year":"2019","journal-title":"ACS Chem. Neurosci."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"10377","DOI":"10.1021\/acs.jmedchem.2c00014","article-title":"SLL-627 Is a Highly Selective and Potent \u03ba Opioid Receptor (KOR) Agonist with an Unexpected Nonreduction in Locomotor Activity","volume":"65","author":"Kong","year":"2022","journal-title":"J. Med. Chem."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1749-6632.2000.tb06672.x","article-title":"Partial opioids: Medications for the treatment of pain and drug abuse","volume":"909","author":"Bidlack","year":"2000","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1016\/j.ddtec.2011.07.007","article-title":"Opioid Peptides: Potential for drug development","volume":"9","author":"Aldrich","year":"2012","journal-title":"Drug Discov. Today Technol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"18396","DOI":"10.1073\/pnas.0910180106","article-title":"Zyklophin, a systemically active selective kappa opioid receptor peptide antagonist with short duration of action","volume":"106","author":"Aldrich","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"FDD17","DOI":"10.4155\/fdd-2019-0022","article-title":"Targeting peripheral \u03f0-opioid receptors for the non-addictive treatment of pain","volume":"1","author":"Beck","year":"2019","journal-title":"Future Drug Discov."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.2174\/092986706777935041","article-title":"Peptides and Peptidomimetics in Medicine, Surgery and Biotechnology","volume":"13","author":"Gentilucci","year":"2006","journal-title":"Curr. Med. Chem."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1038\/sj.bjp.0705763","article-title":"J-M. Peripheral kappa-opioid agonists for visceral pain","volume":"141","year":"2004","journal-title":"Br. J. Pharmacol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/164_2021_461","article-title":"Structural Characterization of KOR Inactive and Active States for 3D Pharmacology and Drug Discovery","volume":"Volume 271","author":"Inan","year":"2021","journal-title":"The Kappa Opioid Receptor. Handbook of Experimental Pharmacology"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/bs.vh.2019.05.006","article-title":"Structure and dynamics of dynorphin peptide and its receptor","volume":"111","author":"Czaplicki","year":"2019","journal-title":"Vitam Horm."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/nature10939","article-title":"Structure of the human \u03ba-opioid receptor in complex with JDTic","volume":"485","author":"Wu","year":"2012","journal-title":"Nature"},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Carbone, J., Ghidini, A., Romano, A., Gentilucci, L., and Musiani, F. (2022). PacDOCK: A Web Server for Positional Distance-Based and Interaction-Based Analysis of Docking Results. Molecules, 27.","DOI":"10.3390\/molecules27206884"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1038\/s41467-020-14889-7","article-title":"Nanobody-enabled monitoring of kappa opioid receptor states","volume":"11","author":"Che","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.cell.2017.12.011","article-title":"Structure of the nanobody-stabilized active state of the kappa opioid receptor","volume":"172","author":"Che","year":"2018","journal-title":"Cell"},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Puls, K., Schmidhammer, H., Wolber, G., and Spetea, M. (2022). Mechanistic Characterization of the Pharmacological Profile of HS-731, a Peripherally Acting Opioid Analgesic, at the \u00b5-, \u03b4-, \u03ba-Opioid and Nociceptin Receptors. Molecules, 27.","DOI":"10.3390\/molecules27030919"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"116509","DOI":"10.1016\/j.bmc.2021.116509","article-title":"C-terminal modified Enkephalin-like tetrapeptides with enhanced affinities at the kappa opioid receptor and monoamine transporters","volume":"51","author":"Munawar","year":"2021","journal-title":"Bioorg. Med. Chem."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"12414","DOI":"10.1021\/acs.jmedchem.1c01082","article-title":"Discovery of an M-Substituted N-Cyclopropylmethyl-7\u03b1-phenyl-6,14-endoethano tetrahydronorthebaine as a Selective, Potent, and Orally Active \u03ba-Opioid Receptor Agonist with an Improved Central Nervous System Safety Profile","volume":"64","author":"He","year":"2021","journal-title":"J. Med. Chem."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1002\/cmdc.202100029","article-title":"Synthesis and Assessment of Fused \u03b2-Carboline Derivatives as Kappa Opioid Receptor Agonists","volume":"16","author":"Yadav","year":"2021","journal-title":"ChemMedChem"},{"key":"ref_110","doi-asserted-by":"crossref","unstructured":"Stefanucci, A., Iobbi, V., Della Valle, A., Scioli, G., Pieretti, S., Minosi, P., Mirzaie, S., Novellino, E., and Mollica, A. (2021). In Silico Identification of Tripeptides as Lead Compounds for the Design of KOR Ligands. Molecules, 26.","DOI":"10.3390\/molecules26164767"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"4769","DOI":"10.1016\/j.bmcl.2016.08.031","article-title":"Structural determinants of diphenethylamines for interaction with the \u03ba opioid receptor: Synthesis, pharmacology and molecular modeling studies","volume":"26","author":"Guerrieri","year":"2016","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_112","first-page":"701","article-title":"Building 3D-structural model of kappa opioid receptor and studying its interaction mechanism with dynorphin A (1-8)","volume":"21","author":"Wan","year":"2000","journal-title":"Acta Pharmacol. Sin."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"34470","DOI":"10.1074\/jbc.M113.515668","article-title":"Chemotype-selective modes of action of kappa-opioid receptor agonists","volume":"288","author":"Vardy","year":"2013","journal-title":"J. Biol. Chem."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"11852","DOI":"10.1073\/pnas.1510117112","article-title":"NMR structure and dynamics of the agonist dynorphin peptide bound to the human kappa opioid receptor","volume":"112","author":"White","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_115","doi-asserted-by":"crossref","unstructured":"Wtorek, K., Ghidini, A., Gentilucci, L., Adamska-Bart\u0142omiejczyk, A., Piekielna-Ciesielska, J., Ruzza, C., Sturaro, C., Cal\u00f2, G., Pieretti, S., and Kluczyk, A. (2022). Synthesis, Biological Activity and Molecular Docking of Chimeric Peptides Targeting Opioid and NOP Receptors. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232012700"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"16346","DOI":"10.1073\/pnas.1918264117","article-title":"Mechanism of \u03b2-arrestin recruitment by the \u03ba-opioid G protein-coupled receptor","volume":"117","author":"Mafi","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_117","doi-asserted-by":"crossref","unstructured":"Piekielna-Ciesielska, J., Artali, R., Azzam, A.A.H., Lambert, D.G., Kluczyk, A., Gentilucci, L., and Janecka, A. (2021). PharmacologicalCharacterization of \u03bc-Opioid Receptor Agonists with Biased G Protein or \u03b2-Arrestin Signaling, and Computational Study of Conformational Changes during Receptor Activation. Molecules, 26.","DOI":"10.3390\/molecules26010013"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"6456","DOI":"10.1021\/acs.biochem.6b00948","article-title":"How oliceridine (TRV-130) binds and stabilizes a \u03ba-opioid receptor. conformational state that selectively triggers G protein signaling pathways","volume":"55","author":"Schneider","year":"2016","journal-title":"Biochemistry"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"e56519","DOI":"10.7554\/eLife.56519","article-title":"Controlling opioid receptor functional selectivity by targeting distinct subpockets of the orthosteric site","volume":"10","author":"Uprety","year":"2021","journal-title":"eLife"}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/28\/1\/346\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T17:55:21Z","timestamp":1760118921000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/28\/1\/346"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,1]]},"references-count":119,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,1]]}},"alternative-id":["molecules28010346"],"URL":"https:\/\/doi.org\/10.3390\/molecules28010346","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,1]]}}}